Fertility Suppression on Testosterone Cypionate: Week-by-Week Timeline of What to Expect

By
Published Updated Last reviewed
Medication safety clinical consultation image for Fertility Suppression on Testosterone Cypionate: Week-by-Week Timeline of What to Expect

Fertility Suppression on Testosterone Cypionate: Week-by-Week Timeline of What to Expect

At a glance

  • Incidence of severe suppression: Approximately 40% of men on exogenous testosterone reach azoospermia; an additional 40% reach severe oligospermia (<1 million/mL), based on WHO contraceptive trials
  • Onset of meaningful sperm-count drop: Weeks 4 to 6 after starting
  • Peak suppression: Weeks 8 to 16 for most men
  • First-line management if fertility is desired: Stop testosterone cypionate; consider clomiphene citrate or hCG-based recovery protocols
  • When to escalate: No sperm count recovery by month 6 post-cessation, or if the patient has a known pre-existing sperm disorder
  • When to discontinue: Any patient planning conception in the near term should discuss stopping before testosterone cypionate is initiated, not after

Why Testosterone Cypionate Suppresses Fertility

The mechanism is a direct consequence of the hypothalamic-pituitary-gonadal (HPG) axis responding to exogenous androgen. When injected testosterone cypionate raises circulating testosterone, the hypothalamus detects the elevated androgen level and reduces gonadotropin-releasing hormone (GnRH) pulse frequency. The pituitary, receiving less GnRH signal, cuts output of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

LH is the primary driver of Leydig cell testosterone production inside the testes. FSH acts directly on Sertoli cells to support sperm maturation. Without adequate LH, intratesticular testosterone (ITT) falls to levels far below serum testosterone. Without FSH, Sertoli cell function degrades. Because spermatogenesis depends on ITT concentrations that are roughly 50 to 100 times higher than serum levels, even modest LH suppression is enough to impair sperm production substantially. This pathway is described in detail in the WHO contraceptive testosterone trial data.

Testosterone cypionate's long ester (half-life approximately 8 days) means suppression is sustained rather than intermittent. A typical 100 to 200 mg weekly injection keeps serum testosterone elevated continuously, giving the HPG axis no window in which to recover during active use.

Weeks 1 to 3: The Suppression Window Opens

LH and FSH begin declining within 24 to 72 hours of the first injection. By the end of week 1, serum LH is often below detectable limits on standard assays in men receiving doses of 100 mg or more per week.

Sperm counts do not drop immediately. Sperm already in the pipeline, having started maturation before the first injection, continue progressing through the epididymis. This lag is important: a semen analysis drawn at week 2 may still appear near-normal and does not reflect the suppression already underway at the testicular level.

Intratesticular testosterone begins falling in this same early window. Studies using testicular biopsy and direct ITT measurement have shown that ITT can fall by more than 90% within the first 2 weeks of exogenous androgen administration, even while serum testosterone is supranormal. The clinical implication is that suppression of the reproductive axis is essentially complete at the hormonal level long before a semen analysis would reveal it.

Weeks 4 to 8: Sperm Counts Begin to Reflect Suppression

The human spermatogenic cycle takes approximately 74 days from spermatogonial stem cell to mature spermatozoon. This is why sperm counts do not collapse overnight. By weeks 4 to 6, sperm counts measured in ejaculate start to decline measurably, because the cohort of sperm that began development just before or around the time of the first injection is now completing maturation in a low-ITT, low-FSH environment.

The 1990 WHO male contraceptive trial using weekly testosterone enanthate (a pharmacologically similar ester) showed that 65% of participants reached azoospermia within 6 months, with the steepest count drop occurring in weeks 4 through 16. Testosterone cypionate behaves comparably given the similar half-lives.

A practical benchmark: a man starting testosterone cypionate at 100 mg per week can reasonably expect his sperm count to be substantially reduced by week 6 and to be approaching its nadir somewhere between weeks 8 and 16, depending on baseline count, testicular volume, and individual HPG axis sensitivity.

Weeks 8 to 16: Nadir and Sustained Azoospermia

This is the window in which azoospermia is most likely to be detected on semen analysis. In the WHO trial, men who reached azoospermia typically did so by week 18 at the latest. For men who do not reach zero, the floor is usually severe oligospermia: counts below 1 million/mL, which carries very low natural conception probability.

Individual variation is real. Roughly 10 to 15% of men on exogenous testosterone do not reach azoospermia even with extended use, possibly due to partial HPG resistance or higher baseline testicular reserve. This does not mean fertility is preserved; severe oligospermia is functionally significant even if technically not zero.

Men who have already been on testosterone cypionate for several months before a fertility question arises are often in this sustained nadir phase. Their hormonal picture at this stage typically shows: very low or undetectable serum LH and FSH, testicular atrophy of variable degree, and azoospermia or near-azoospermia on semen analysis. Clinical endocrinology guidelines from the Endocrine Society confirm this pattern and explicitly flag TRT as a cause of male infertility that requires counseling before initiation.

Months 4 to 6 After Stopping: The Recovery Phase Begins

Once testosterone cypionate is discontinued, the ester clears over approximately 3 to 4 weeks. As serum testosterone falls toward baseline, GnRH pulse frequency resumes, and LH and FSH begin to rise. The testes receive the restart signal, but the spermatogenic cycle still requires approximately 74 days to produce new sperm from reactivated stem cells.

Most men begin to see sperm returning on semen analysis at 3 to 6 months post-cessation. A 2013 meta-analysis by Liu et al. in the Journal of Clinical Endocrinology and Metabolism examined recovery data from 1,549 men across multiple hormonal contraceptive trials and found that 67% recovered to baseline sperm concentrations within 6 months, 90% within 12 months, and 96% within 24 months.

Recovery is not guaranteed. Older age at cessation, longer duration of use, pre-existing testicular dysfunction, and smaller baseline testicular volume are all associated with slower or incomplete recovery. A man who used testosterone cypionate for 10 years has a different recovery outlook than one who used it for 18 months.

When Recovery Is Delayed: Options for Accelerating Return

If sperm counts have not begun recovering by 6 months after stopping testosterone cypionate, or if a patient has a time-sensitive fertility goal, several pharmacologic options exist.

Human chorionic gonadotropin (hCG): hCG mimics LH and directly stimulates Leydig cell ITT production. It is the most commonly used agent to accelerate post-TRT recovery. Typical protocols use 1,500 to 3 to 000 IU subcutaneously two to three times per week. Some clinicians co-administer FSH analogs to support Sertoli cell function simultaneously. A 2005 study by Coviello et al. demonstrated that low-dose hCG (500 IU every other day) could maintain ITT and spermatogenesis even alongside exogenous testosterone in some men, supporting its role as a recovery agent.

Clomiphene citrate: A selective estrogen receptor modulator (SERM) that blocks estrogen feedback at the hypothalamus and pituitary, clomiphene increases endogenous LH and FSH output. Typical doses of 25 to 50 mg daily or every other day are used off-label to stimulate HPG axis restart post-TRT.

FSH supplementation: Recombinant FSH or human menopausal gonadotropin (hMG) is sometimes added when FSH recovery lags behind LH recovery, which can occur after prolonged suppression.

Referral to a reproductive urologist or reproductive endocrinologist is appropriate when first-line restart attempts are not producing sperm count improvements at 3 to 6 months of recovery treatment.

Preserving Fertility Before Starting Testosterone Cypionate

Any man of reproductive age considering testosterone cypionate should be counseled on fertility preservation options before the first injection. Sperm banking is the most straightforward option: a single cryopreserved sample takes less than an hour and gives the patient a preserved baseline regardless of how TRT affects his sperm count later. Costs vary but are generally far lower than the cost of subsequent fertility interventions.

Men who want to maintain fertility while on TRT have limited options. Low-dose hCG co-administration has the best evidence for partially maintaining ITT and spermatogenesis during TRT, though it does not reliably maintain sperm counts at natural levels. The Endocrine Society's male hypogonadism clinical practice guideline specifically states that TRT is contraindicated in men actively trying to conceive and recommends gonadotropin therapy instead.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet. 1990;336(8721):955-959. https://pubmed.ncbi.nlm.nih.gov/2054958/
  2. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet. 2006;367(9520):1412-1420. https://pubmed.ncbi.nlm.nih.gov/16985920/
  3. Coviello AD, Matsumoto AM, Bremner WJ, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005;90(5):2595-2602. https://pubmed.ncbi.nlm.nih.gov/15784841/
  4. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://www.endocrine.org/clinical-practice-guidelines/testosterone-therapy
  5. Rambhatla A, Mills JN, Rajfer J. The role of estrogen modulators in male hypogonadism and infertility. Rev Urol. 2016;18(2):66-72. https://pubmed.ncbi.nlm.nih.gov/27601965/
  6. Nieschlag E, Vorona E. Mechanisms in endocrinology: medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. Eur J Endocrinol. 2015;173(2):R47-R58. https://pubmed.ncbi.nlm.nih.gov/25805893/